News & Blogs

Price Controls Could Prevent the Next ‘Miracle Drug’

The death rate from cancer in the United States has fallen by more than one-third since 1991. HIV-related mortality has dropped ninefold since 1995. Death rates for Alzheimer’s, chronic respiratory diseases, and stroke have all declined in recent years, too. These gains didn’t happen by accident. They’re the result of decades of medical innovation — from antiretroviral therapy drugs to breakthrough cancer treatments — that have helped people live longer, healthier lives. These pharmaceutical breakthroughs…

Learn More

Hospital Consolidation and Tax Exemptions Are an Overlooked Health Care Crisis

Most of the public anger over the cost of American health care in recent years has been directed toward Congress, the insurance companies, and the pharmaceutical companies – but the latest national health expenditure data shows hospitals are by far the biggest driver of increased health care costs.  As a result of government payment, regulatory, and tax policies, hospitals have evolved into enormous integrated “health systems.”  Most of these systems are operated as tax-exempt non-profits despite vast…

Learn More

History Has Proven Price Controls Do Not Work

The new U.S.-U.K. pharmaceutical agreement is an important reminder that there is a smarter way to address global drug-pricing disparities than by importing artificial price controls into the United States. If the goal is to make medicines more affordable without undermining the innovation pipeline, trade policy that pressures foreign governments to pay more for the research and development they benefit from is far preferable to Most Favored Nation-style pricing rules that cap what Americans pay…

Learn More

A Prescription for Decline: Biden’s Drug Price Controls Are Hurting the Patients It Promised to Serve

Four years after its passage, the Inflation Reduction Act’s (IRA) drug pricing provisions have not delivered the seamless savings the Left promised. Instead, a growing body of peer-reviewed research, investor surveys, and clinical trial data has revealed that this law is not only problematic to its core, but also riddled with structural flaws: specifically, the creation of a small molecule “pill penalty.”

Learn More

The Real Profiteers in Healthcare Aren’t Drugmakers

Pressure is building on Capitol Hill for Congress to codify President Trump’s “most favored nation” drug-pricing initiative into law. The administration has already struck deals with more than a dozen drugmakers to sell medicines to Medicaid, the federal-state health plan for low-income individuals and the disabled, at the lowest prices paid by other developed nations. Now lawmakers are debating whether to impose the same framework across the U.S. market.

Learn More

Applaud Trade, Avoid Price Controls

In an era where American leadership on the global stage has been redefined by bold, unapologetic negotiation, President Trump has proven himself a master of the art of the deal and using existing and creating new leverage. From renegotiating NAFTA into the USMCA in the first term, extracting concessions from China through targeted tariffs, to pressuring European allies on defense spending and trade imbalances, his administration has wielded trade policy like a precision tool.  These…

Learn More

Five ways for Republicans to win on health care affordability

For most of the past 40 years, pollsters have asked voters: Which party do you trust more on health care? The answer has been pretty much the same over this whole period. Voters trust the Democrats more, and sometimes by a 2-1 margin. Republicans shouldn’t be afraid of the issue. Democrats have pretty much unilaterally designed the medical care system we have now. They own it. The outcome isn’t happy. We are getting spiraling costs with less access and, in…

Learn More

Republicans Can Win on Healthcare Affordability

For most of the last 40 years, pollsters have asked voters: Which party do you trust more on healthcare? The answer has been pretty much the same over this whole period. Voters trust Democrats more, sometimes by a two-to-one margin. When I’ve asked my Republican politicos why that is, the answer I typically receive is: Our party doesn’t do healthcare. Then they crouch in the fetal position. Well, the GOP certainly better start “doing healthcare,”…

Learn More